<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744315</url>
  </required_header>
  <id_info>
    <org_study_id>UP3549</org_study_id>
    <nct_id>NCT00744315</nct_id>
  </id_info>
  <brief_title>Induced Angiogenesis by Genic Therapy in Advanced Ischemic Cardiomyopathy</brief_title>
  <acronym>THEANGIOGEN</acronym>
  <official_title>Induced Angiogenesis by Genic Therapy With VEGF165 in Advanced Ischemic Cardiomyopathy - Historical Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Cardiologia do Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Cardiologia do Rio Grande do Sul</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human Vascular Endothelial Grown Factor 165 (hVEGF165) administration is promising therapy
      induces a new vessels, arterioles and capillaries in regions whose revascularization surgery
      is not possible by direct or by percutaneous angioplasty. This study aims to evaluate the
      clinical effects and safety of gene therapy with hVEGF165 in patients with advanced coronary
      artery disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">May 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical finds</measure>
    <time_frame>eighteen months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ischemic Cardiopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Controlled</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mini-thoracotomy for intramyocardial injection of VEGF165</intervention_name>
    <description>Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis coronary artery disease and symptomatic, despite optimal pharmacologic
             therapy

          -  Left ventricular dysfunction - left ventricular ejection fraction between 60% and 25%
             by echocardiogram

          -  Non-conventional revascularization, as seen by cineangiocardiography, attested by
             interventional cardiologist and cardiac surgeon

          -  Age below 75 years

          -  Absence of neoplasm

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato AK Kalil, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Scientific Direction - Institute of Cardiology of Rio Grande do Sul / FUC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Imarilde Giusti, MD</last_name>
    <phone>555132192802</phone>
    <phone_ext>23</phone_ext>
    <email>pesquisa@cardiologia.org.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Cardiology of Rio Grande do Sul / FUC</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90620001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imarilde Giusti, MD</last_name>
      <phone>555132303600</phone>
      <phone_ext>3652</phone_ext>
      <email>kalil.pesquisa@cardiologia.org.br</email>
    </contact>
    <investigator>
      <last_name>Imarilde Giusti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>August 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <last_update_submitted>October 14, 2008</last_update_submitted>
  <last_update_submitted_qc>October 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Imarilde Giusti</name_title>
    <organization>Institute of Cardiology of Rio Grande do Sul/FUC</organization>
  </responsible_party>
  <keyword>myocardial revascularization</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>genetics, medical</keyword>
  <keyword>Angiogenesis Inducing Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 21, 2011</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>December 7, 2011</submitted>
    <returned>January 11, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

